Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

Sarraju, Ashish; Bakris, George L.; Cannon, Christopher P.; Cherney, David Z.I.; Damaraju, C. V.; Figtree, Gemma A.; Gogate, Jagadish; Greene, Tom; Heerspink, Hiddo J.L.; Januzzi, James L.; Neal, Bruce; Jardine, Meg; Blais, Jaime D.; Kosiborod, Mikhail; Levin, Adeera; Lingvay, Ildiko; Weir, Matthew R.; Perkovic, Vlado; Mahaffey, Kenneth W.

doi:10.1016/j.jacc.2022.08.772

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ESC guidelines recommend SGLT2 inhibitors as the cornerstone of drug therapy for heart failure, regardless of whether they have combined diabetes (34). Recent clinical trials, including CVD-REAL Nordic (35), EMPA-REG OUTCOME (36)(37)(38), and the CANVAS project (39,40), confirmed the effectiveness of SGLT2 inhibitors in patients with coronary heart disease.…”

Section: Sgltinhibitor Improves the Prognosis Of Patients With Chdmentioning

confidence: 97%

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Zhang,

Deng,

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.

show abstract

Section: Sgltinhibitor Improves the Prognosis Of Patients With Chdmentioning

confidence: 97%

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Zhang,

Deng,

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Auch in den Langzeitstudien zu mikrovaskulären Endpunkten mit der Substanzklasse der SGLT-2 Inhibitoren (SGLT-2 = sodium glucose transporter) wurde die anhaltende prozentuale Abnahme der GFR als ein Endpunkt betrachtet [58,59,60,61,62,63,64,65,66,67,68,69,70,71]. Eine Verdopplung des Serum-Kreatinins ist ein besonders starker Prädiktor für eine Nierenerkrankung im Endstadium.…”

Section: Diabetic Retinopathy Severity Scale (Drss)unclassified

Endpunkte zu mikrovaskulären Folgekomplikationen: klinische Endpunkte, patientenberichtete Endpunkte und Surrogatendpunkte, Methodik von Surrogatvalidierungsstudien

Gallwitz,

Kellerer,

Müller-Wieland

et al. 2023

Diabetologie und Stoffwechsel

View full text Add to dashboard Cite

ZusammenfassungFür die Bewertung und die Vergleichbarkeit klinischer Langzeitstudien zur Sicherheit und/oder Effektivität verschiedener Therapieformen bei chronischen Erkrankungen sind möglichst vergleichbare und homogene vorab festgelegte Endpunkte und Surrogatparameter wichtig. Am Beispiel des Diabetes mellitus Typ 2 als chronische Erkrankung wird die Erhebung mikrovaskulärer Endpunkte und von Surrogatparametern bei der diabetesbedingten Retinopathie und Nephropathie dargelegt und diskutiert.

show abstract

“…Clinical studies affirmed improved glycemic control but it soon became apparent their actions extended far beyond lowering blood sugar. SGLT2 inhibitors induced weight loss, lowered hypertension, reduced cardiac arrhythmias, decreased proteinuria, delayed CKD progression, and improved outcomes in HF [407][408][409][410][411][412][413][414]. Effects were mediated by increased microvascular and mitochondrial function [415][416][417][418][419][420][421][422][423].…”

Section: Omnia Incipit In Sanguinementioning

confidence: 99%

Energy Dynamics in Chronic Heart Failure, Chronic Kidney Disease & the Cardiorenal Syndrome: A New Causal Paradigm

Thorp¹,

Thorp²,

Northrup³

et al. 2023

G Med Sci

View full text Add to dashboard Cite

In this paper we examine HF and CKD through the lens of a new causal paradigm: as a conjoined energy deficiency syndrome whose progression is governed by impaired energy generation by the cardiovascular system leading to subsequent deterioration of blood energy dynamics. Due to the immense complexity of this topic our intention is not to go into unnecessary and laborious detail on specific cellular and molecular aspects of the syndromes but, instead, to use illustrative examples to establish overarching principles and to highlight the connection between the deteriorating energy field and all resultant aberrations. Indeed, once the energy dynamics are recognized cellular and molecular descriptions become superfluous. Our use of the term 'causal' is meant to imply that future breakthroughs in the treatment (and potential reversal) of these complex disease states necessarily entails recognition and correction of underlying energy deficits.

show abstract

Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

Cited by 7 publications

References 25 publications

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Endpunkte zu mikrovaskulären Folgekomplikationen: klinische Endpunkte, patientenberichtete Endpunkte und Surrogatendpunkte, Methodik von Surrogatvalidierungsstudien

Energy Dynamics in Chronic Heart Failure, Chronic Kidney Disease & the Cardiorenal Syndrome: A New Causal Paradigm

Contact Info

Product

Resources

About